EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

In vitro CAR-T cell killing: validation of the potency assay

Claudia Piccinini, Silvia Carloni, Chiara Arienti, Elena Pancisi, Francesca Fanini, Sara Pignatta, Valentina Soldati, Monica Stefanelli, Anna Maria Granato, Giovanni Martinelli, Laura Ridolfi, Massimiliano Petrini

Cancer Immunology, Immunotherapy · 02.07.2024 · 73 (9)

DOI: 10.1007/s00262-024-03753-y ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 02.07.2024. Verfasst von Claudia Piccinini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-Gene Therapy Factory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Maroncelli 40, 47014, Meldola, Italy. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For advanced therapy medicinal products, the development and validation of potency assays are required, in accordance with international guidelines, to characterise the product and obtain reliable and consistent data. Our purpose was to validate the killing assay for the evaluation of autologous anti-CD19 chimeric antigen receptor (CAR) T potency. We used CD4 + and CD8 + lymphocytes or anti-CD19 CAR-T cells as effector cells and REH (CD19 +) or MOLM-13 (CD19 −) cell lines as target cells. After co-culturing target and effector cells (1:1 ratio) for 24 h, samples were labelled with 7-AAD, anti-CD3 and anti-CD19 antibodies and the frequency of CD19 + dead cells was evaluated by flow cytometry. In order to verify the CAR-T specificity for the CD19 + target, the co-culture between CAR-T and REH or MOLM-13 at different effector-to-target ratios was scheduled. Moreover, not transduced CD4 + and CD8 + lymphocytes were tested in comparison with CAR-T from the same donor to demonstrate the assay specificity. Linearity and accuracy were evaluated, and established acceptance criteria were compiled for both parameters (r 2 ≥ 0.97 for linearity and average relative error ≤ 10% for accuracy). Furthermore, the method was considered robust when performed between 23 and 25 h of co-culture, and the intra-assay, inter-assay and inter-day precision was obtained. Finally, in order to verify the inter-analyst precision, the test was executed by three different operators and the intra-class correlation coefficient was > 0.4 in both cases. In conclusion, we consider this CAR-T potency assay as validated and usable in all steps of product development and quality control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveAntigens, CD19HumansCoculture TechniquesCD8-Positive T-LymphocytesCytotoxicity, ImmunologicCell Line, TumorCD4-Positive T-Lymphocytes

Stichwörter der Autor:innen

CAR-TKillingPotencyValidation

Substanzen

Receptors, Chimeric AntigenAntigens, CD19

Autor:innen und Institutionen

  • Immuno-Gene Therapy Factory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Maroncelli 40, 47014, Meldola, Italy.
  • Immuno-Gene Therapy Factory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via Maroncelli 40, 47014, Meldola, Italy. sara.pignatta@irst.emr.it.
  • Scientific Direction, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Experimental and Clinical Oncology of Immunotherapy and Rare Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Förderung

  • Ministero della Salute

Zitieren

APA

Piccinini, C., Carloni, S., Arienti, C., Pancisi, E., Fanini, F., Pignatta, S., Soldati, V., Stefanelli, M., Granato, A. M., Martinelli, G., Ridolfi, L., & Petrini, M. (2024). In vitro CAR-T cell killing: validation of the potency assay. Cancer Immunology, Immunotherapy, 73(9). https://doi.org/10.1007/s00262-024-03753-y

Vancouver

Piccinini C, Carloni S, Arienti C, Pancisi E, Fanini F, Pignatta S, et al. In vitro CAR-T cell killing: validation of the potency assay. Cancer Immunology, Immunotherapy. 2024;73(9). doi:10.1007/s00262-024-03753-y

BibTeX
@article{Piccinini2024,
  author = {Piccinini, Claudia and Carloni, Silvia and Arienti, Chiara and Pancisi, Elena and Fanini, Francesca and Pignatta, Sara and Soldati, Valentina and Stefanelli, Monica and Granato, Anna Maria and Martinelli, Giovanni and Ridolfi, Laura and Petrini, Massimiliano},
  title = {In vitro CAR-T cell killing: validation of the potency assay},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {9},
  doi = {10.1007/s00262-024-03753-y}
}
Kostenlos starten →